Display Settings:

Format

Send to:

Choose Destination
    Cancer Invest. 2009 Jun;27(5):549-60.

    Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.

    Source

    Department of Urology, Mayo Clinic/Foundation, Rochester, Minnesota 55905, USA.

    Abstract

    To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology. Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer. Furthermore, CpG site hypermethylation of genes FLNC, EFS, ECRG4, PITX2, PDLIM4, and KCNMA1 were associated with prediction of biochemical, local, and systemic recurrence of prostate cancer.

    PMID:
    19229700
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2693083
    Free PMC Article

    Images from this publication.See all images (3) Free text

    Figure 3
    Figure 1
    Figure 2

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk